| Identification | More | [Name]
Esomeprazole magnesium trihydrate | [CAS]
217087-09-7 | [Synonyms]
bis(5-methoxy-2-[(s)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1h-benzylimidazole-1-yl) magnesium trihydrate
ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM TRIHYDRATE
(T-4)-Bis[5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazolato]magnesium
Nexium
ESOPMEPRAZOLE MG TRIHYDRATE
Bis(5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzylimidazole-1-yl) magnesium trihydrate
ESOMEPRAZOLE MAGNESIUM TRIHYDRATE USP | [EINECS(EC#)]
669-839-3 | [Molecular Formula]
C34H42MgN6O9S2 | [MDL Number]
MFCD07698573 | [Molecular Weight]
767.17 | [MOL File]
217087-09-7.mol |
| Chemical Properties | Back Directory | [Appearance]
Off-White Powder | [Melting point ]
184-189°C (dec.) | [storage temp. ]
Keep in dark place,Inert atmosphere,Store in freezer, under -20°C | [solubility ]
Slightly soluble in water, soluble in methanol, practically insoluble in heptane. | [form ]
neat | [color ]
White to off-white | [Usage]
S-Form of Omeprazole. Gastric proton-pump inhibitor | [InChI]
InChI=1S/2C17H18N3O3S.Mg.H2O/c2*1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17;;/h2*5-8H,9H2,1-4H3;;1H2/q2*-1;+2; | [InChIKey]
VEVZQDGATGBLIC-UHFFFAOYSA-N | [SMILES]
C(C1N=CC(C)=C(OC)C=1C)S1C2[N-]C3=CC(OC)=CC=C3N=2[Mg+2]2(O=S(CC3N=CC(C)=C(OC)C=3C)C3[N-]C4=CC(OC)=CC=C4N2=3)O=1.O | [CAS DataBase Reference]
217087-09-7(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Chemical Properties]
Off-White Powder | [Uses]
esomeprazole magnesium trihydrate for the healing of peptic ulcers associated with non-steroidal anti-inflammatory drug NSAID (non-selective and COX-2 selective) therapy.
- Zollinger-Ellison syndrome
- Peptic ulcer, site unspecified
- Duodenal ulcer
- Gastric ulcer
- Gastro-oesophageal reflux disease
Esomeprazole belongs to the family of medications known as proton pump inhibitors (PPIs). Esomeprazole is registered by the Therapeutic Goods Administration (TGA) for the following indications:
- Gastro-Oesophageal Reflux Disease (GORD):
- treatment of erosive reflux oesophagitis;
- long-term management of patients with healed oesophagitis to prevent relapse;
- symptomatic treatment of gastro-oesophageal reflux disease (GORD).
In combination with appropriate antibiotics for:
- healing of duodenal ulcer associated with Helicobacter pylori;
- eradication of Helicobacter pylori in patients with active or healed peptic ulcer.
- Short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug (NSAID) (non-selective and COX-2 selective) therapy.
- Healing of gastric ulcers associated with non-steroidal anti-inflammatory drug NSAID (non-selective and COX-2 selective) therapy.
- Prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug NSAID (non-selective and COX-2 selective) therapy in patients at risk.
| [Uses]
S-Form of Omeprazole. Gastric proton-pump inhibitor | [Brand name]
Nexium (AstraZeneca). | [Biological Activity]
Esomeprazole magnesium trihydrate ((S)-Omeprazole magnesium trihydrate) is a potent, orally active H+, K+-ATPase inhibitor. Esomeprazole magnesium trihydrate has the potential for upper intestinal disorders and gastroesophageal reflux disease research. Esomeprazole magnesium trihydrate acts as an exosome inhibitor by blocking the exosome release by inhibiting V-H+-ATPases.
|
|
|